GSA Capital Partners LLP Trims Stake in Royalty Pharma plc (NASDAQ:RPRX)

GSA Capital Partners LLP lessened its holdings in Royalty Pharma plc (NASDAQ:RPRX) by 7.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 44,535 shares of the biopharmaceutical company’s stock after selling 3,472 shares during the period. GSA Capital Partners LLP’s holdings in Royalty Pharma were worth $1,260,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Allspring Global Investments Holdings LLC boosted its stake in Royalty Pharma by 4,335.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 2,750 shares of the biopharmaceutical company’s stock worth $84,000 after buying an additional 2,688 shares during the period. Russell Investments Group Ltd. increased its holdings in Royalty Pharma by 24.5% in the 1st quarter. Russell Investments Group Ltd. now owns 402,143 shares of the biopharmaceutical company’s stock valued at $12,224,000 after purchasing an additional 79,176 shares during the last quarter. ProShare Advisors LLC raised its position in Royalty Pharma by 9.7% in the first quarter. ProShare Advisors LLC now owns 31,305 shares of the biopharmaceutical company’s stock valued at $951,000 after purchasing an additional 2,764 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in Royalty Pharma by 12.1% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 181,743 shares of the biopharmaceutical company’s stock worth $5,520,000 after purchasing an additional 19,642 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of Royalty Pharma by 15.9% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 216,435 shares of the biopharmaceutical company’s stock worth $6,573,000 after buying an additional 29,672 shares during the period. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on RPRX shares. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. Citigroup cut their price target on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. Finally, The Goldman Sachs Group lifted their price objective on shares of Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $41.67.

Royalty Pharma Stock Down 1.0 %

Shares of Royalty Pharma stock opened at $25.58 on Friday. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.64. Royalty Pharma plc has a 52-week low of $25.20 and a 52-week high of $31.66. The company has a market capitalization of $15.18 billion, a P/E ratio of 13.24, a P/E/G ratio of 3.80 and a beta of 0.47. The company has a 50 day moving average of $27.60 and a 200 day moving average of $27.49.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a dividend of $0.21 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.28%. Royalty Pharma’s payout ratio is currently 43.52%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.